Revvity stock gains after beating first-quarter profit estimates By Investing.com

Revvity beat first-quarter adjusted EPS expectations at $1.06 versus $1.02 consensus, but lowered 2026 adjusted profit guidance to $5.20-$5.30 from $5.35-$5.45, below the $5.39 analyst estimate. The company also said it will sell its immunodiagnostics business in China, which accounted for about 6% of fiscal 2025 revenue. Shares rose 2.7% in premarket trading despite the softer forward outlook.

Analysis

The market is treating this as a clean beat, but the more important signal is management choosing to trade away near-term visibility for a lower-quality revenue stream. That usually improves headline margins and reduces geopolitical exposure, but it also removes a quasi-embedded growth option in China just as domestic diagnostics competition is getting structurally harder. The immediate winner is the core ex-China franchise if capital and management attention get redeployed into higher-return segments; the loser is any investor underwriting a stable multiple on the assumption that the business is still diversified across end markets.

Second-order, this is less about the size of the divestiture and more about what it implies for forward estimates: once one non-core asset is exited, the market often extrapolates a broader pruning cycle, which can pressure revenue growth expectations for 2-3 quarters even if EPS holds up. That creates a classic quality-vs-growth tension: near-term margin support can coexist with a de-rating if sell-side models begin to strip out low-single-digit growth contributions that were previously assumed to be sticky. In healthcare tools, that matters because multiple support is more sensitive to organic growth durability than to one-time earnings beats.

The contrarian read is that the stock may be over-penalized on guidance while underappreciating strategic simplification. If the China exposure was disproportionately volatile, the implied forward multiple should arguably expand on lower risk, not contract on lower topline. The key question over the next 1-2 quarters is whether management can offset the lost revenue with better mix, share gains, or buybacks; if not, the market will correctly discount this as a shrinking mid-teens multiple business rather than a compounder.

For catalysts, watch the next two reporting cycles for margin bridge commentary and any indication the divestiture proceeds are being returned to shareholders versus used for M&A. If proceeds are allocated to accretive repurchases at current valuations, the downside to guidance could be offset quickly; if not, the stock risks remaining a value trap with low growth and a compressed premium multiple.

Key Decisions for Investors

• Tactically sell strength in RVTY over the next 1-2 weeks; the beat is likely to fade once the market focuses on the lowered forward earnings path and China exit haircut.
• Consider a pairs trade: long ILMN or TMO vs short RVTY for 1-3 months, betting that larger platforms with stronger organic growth narratives keep their premium while RVTY de-rates on slower top-line visibility.
• If holding RVTY, hedge with a short-dated call overwrite into the next earnings cycle; the likely near-term upside is capped unless management proves the divestiture improves capital returns.
• Watch for a post-close or next-quarter announcement on buybacks funded by sale proceeds; if announced, re-enter on weakness because the market may be underestimating the accretion from shrinking the denominator.
• Do not chase the premarket move; the better entry is after the first estimate revisions cycle, when consensus has fully incorporated the lower guide and any multiple reset is complete.